search

Active clinical trials for "Colitis, Ulcerative"

Results 991-1000 of 1080

Objective Perfusion Rate Assessment by Near-infrared Fluorescence in Ileal Pouch Formation and Ileal-pouch-anal...

Ulcerative ColitisColorectal Cancer6 more

In this prospective, non-randomized cohort study, real-time intraoperative visualization using near-infrared-fluorescence by indocyanine green injection (ICG-NIRF) is performed at three time points during ileal pouch reconstruction. Postoperatively, a detailed software-based assessment of each pouch recording is performed to determine the objective ICG-NIRF perfusion rate, which is then correlated with the 30 day postoperative clinical outcome including occurrence of anastomotic leak of the pouch.

Unknown status9 enrollment criteria

Indicators Predicting Surgery in Acute Severe Ulcerative Colitis(ASUC)

Ulcerative Colitis AcuteSurgery

Acute severe ulcerative colitis [ASUC] patients have high risk of no response to medical treatments and might miss the best timing for surgery when waiting for the medical response. Thus, we investigated whether biomarkers which could early predict the surgery risk of patients with ASUC on admission.

Completed2 enrollment criteria

Detection of Helicobacter Pylori in Ulcerative Colitis Patients

Inflammatory Bowel Diseases

Helicobacter pylori (H. pylori) infection is one of the most common infectious diseases in humans.

Unknown status2 enrollment criteria

Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa

ColitisUlcerative

Alterations in the intestinal microbiota have been associated to disease pathogenesis in ulcerative colitis. Refractory disease to standard medical therapy as corticosteroids often leads to an unfavourable course in patients suffering from this disorder. This study proposal aims at investigating changes in the intestinal microbiota that can predict a therapy refractory course of ulcerative colitis (UC) and may be used to identify high risk patients in an early phase of their disease.

Completed8 enrollment criteria

Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy...

Ulcerative Colitis

Ulcerative colitis (UC) is a chronic remitting and relapsing inflammatory bowel disease. The pathogenesis is multifactorial, involving genetic predisposition, epithelial barrier defects, dysregulated immune responses, and environmental factors. It is diagnosed through colonoscopy and histological evidence of mucosal inflammation involving predominantly the rectum and potentially extending continuously up to the proximal segments of the colon. The patients affected present with severe abdominal pain, bloody diarrhea together with extraintestinal manifestations such as peripheral arthritis, pyoderma gangrenosum, erythema nodosum, ankylosing spondylitis and many others. The last 20 years have been profitable from the therapeutical point of view thanks to the advent of biological drugs which are derived from a living organism or its products including antibodies, interleukins and other molecules capable to target specific cellular pathways and to modulate different mechanisms such as blocking the actions of cytokines or white cells movement in the gut. More recently new promising alternatives seems to be the so-called small molecule drugs which are chemically derived low molecular weight compounds capable to enter the cell to regulate its functions and more generally biological processes like inflammation. In the last years, the therapeutic offer for ulcerative colitis patients has been enriched with the advent of biologics with different mechanism of action and very recently with the availability of the small molecules. Currently the available therapeutic options for ulcerative colitis include topic and systemic mesalazine, topic and systemic glucocorticoids, immunosuppressants (thiopurines), biological drugs (anti-tumor necrosis factor α (TNFα), inhibitor of α4β7 integrin, anti-IL12-23) and small molecules (JAK inhibitors). However, if on the one hand the therapeutical enrichment has clearly improved the disease rate control, still there is the need to perform sequencing study to stratify the available options to provide the best and most appropriate patient-oriented management.

Completed6 enrollment criteria

Nutritional State and Intake Nutrients Assessment in Ulcerative Colitis

Ulcerative Colitis in Remission

The purpose of this study is to determine the reason patients are deficient in nutrients intake such as antioxidants vitamins.

Completed5 enrollment criteria

Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis

Crohn's DiseaseUlcerative Colitis

This case-control study will screen for dysmenorrhea and assess severity of menstrual symptoms in menstruating women with CD and UC compared with healthy age-matched controls. IBD activity will be characterized using previously validated clinical disease activity indices. General and health-related quality of life will be assessed using validated measures.

Completed14 enrollment criteria

Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)

Ulcerative Colitis

The purpose of this protocol is: To quantify the prevalence of adherence to topical mesalamine in patients with UC To describe the determinants of medication adherence in patients with UC prescribed topical mesalamine

Completed6 enrollment criteria

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel...

Crohn's DiseaseUlcerative Colitis

An increase prevalence of CMV, EBV and or HHV-6 in diseased tissue of inflammatory bowel disease would suggest a role for these viruses in the etiology and/or exacerbation of IBD, whereas their absence would preclude such association.

Completed4 enrollment criteria

OTIS Vedolizumab Pregnancy Exposure Registry

ColitisUlcerative1 more

The purpose of this study is to assess the prevalence of major structural birth defects in infants of female participants with ulcerative colitis (UC) or Crohn's disease (CD) exposed to vedolizumab during pregnancy, compared to participants with UC or CD exposed to other biologic agents.

Completed21 enrollment criteria
1...99100101...108

Need Help? Contact our team!


We'll reach out to this number within 24 hrs